Skip to main content

Table 1 Baseline characteristics of patients with eGFR ≥ 30 who received levosimendan versus dobutamine alone

From: Levosimendan use in patients with acute heart failure and reduced ejection fraction with or without severe renal dysfunction in critical cardiac care units: a multi-institution database study

Variable

Valid N

Before PSM

After PSM

Levosimendan

(n = 102)

Dobutamine

(n = 567)

STD

Levosimendan

(n = 82)

Dobutamine

(n = 145)

STD

Age, year*

669

65.8 ± 15.3

64.3 ± 15.1

0.10

65.5 ± 14.7

65.7 ± 15.6

− 0.01

Male*

669

76 (74.5)

437 (77.1)

− 0.06

64 (78.0)

105 (72.4)

0.13

LVEF, %*

669

28.7 ± 6.8

28.3 ± 7.8

0.05

27.7 ± 6.7

27.7 ± 7.8

 < 0.01

eGFR, mL/min/1.73m2*

669

66.2 ± 31.9

65.8 ± 29.1

0.01

66.6 ± 32.5

67.6 ± 29.5

− 0.03

Inotropic agents during the index admission

 Dopamine*

669

24 (23.5)

67 (11.8)

0.31

15 (18.3)

24 (16.6)

0.05

 Norepinephrine*

669

15 (14.7)

87 (15.3)

− 0.02

12 (14.6)

20 (13.8)

0.02

 Epinephrine*

669

8 (7.8)

112 (19.8)

− 0.35

6 (7.3)

11 (7.6)

− 0.01

AMI during the index admission*

669

35 (34.3)

85 (15.0)

0.46

20 (24.4)

37 (25.5)

− 0.03

PCI during the index admission*

669

23 (22.5)

41 (7.2)

0.44

12 (14.6)

21 (14.5)

 < 0.01

Myocarditis during the index admission*

669

6 (5.9)

8 (1.4)

0.24

3 (3.7)

2 (1.4)

0.15

Mechanical ventilator*

669

52 (51.0)

233 (41.1)

0.20

41 (50.0)

59 (40.7)

0.19

IABP*

669

34 (33.3)

26 (4.6)

0.79

14 (17.1)

20 (13.8)

0.09

ICU days

669

7 [4, 11]

2 [0, 6]

NA

7 [3, 10]

3 [0, 7]

NA

Admission days

669

19 [15, 36]

19 [12, 31]

NA

20 [15, 38]

18 [12, 29]

NA

Risk score*

 SOFA

669

6.4 ± 2.0

6.8 ± 2.2

− 0.20

6.4 ± 2.0

6.2 ± 1.8

0.10

 APACHE III

669

37.5 ± 17.6

32.4 ± 16.2

0.31

37.3 ± 18.2

35.5 ± 19.0

0.10

Comorbidities

 Atrial fibrillation

669

39 (38.2)

216 (38.1)

0.00

35 (42.7)

47 (32.4)

0.21

 Diabetes mellitus

669

44 (43.1)

266 (46.9)

− 0.08

38 (46.3)

85 (58.6)

− 0.25

 Hypertension

669

63 (61.8)

391 (69.0)

− 0.15

51 (62.2)

107 (73.8)

− 0.25

 Dyslipidemia

669

70 (68.6)

301 (53.1)

0.32

54 (65.9)

90 (62.1)

0.08

Baseline medications

 Aspirin

669

78 (76.5)

379 (66.8)

0.21

61 (74.4)

101 (69.7)

0.11

 Clopidogrel

669

58 (56.9)

273 (48.1)

0.18

45 (54.9)

83 (57.2)

− 0.05

 Ticagrelor

669

41 (40.2)

88 (15.5)

0.57

26 (31.7)

27 (18.6)

0.31

 Beta-blockers

669

97 (95.1)

474 (83.6)

0.38

79 (96.3)

122 (84.1)

0.42

 ACEi

669

65 (63.7)

314 (55.4)

0.17

49 (59.8)

79 (54.5)

0.11

 ARBs

669

73 (71.6)

375 (66.1)

0.12

59 (72.0)

98 (67.6)

0.10

 MRA

669

73 (71.6)

443 (78.1)

− 0.15

61 (74.4)

111 (76.6)

− 0.05

 Digoxin

669

42 (41.2)

268 (47.3)

− 0.12

39 (47.6)

65 (44.8)

0.05

 Amiodarone

669

72 (70.6)

298 (52.6)

0.38

60 (73.2)

60 (41.4)

0.68

 Ivabradine

669

43 (42.2)

117 (20.6)

0.48

32 (39.0)

34 (23.4)

0.34

Baseline laboratory data

 Hemoglobin, g/dl

664

12.1 ± 2.5

11.8 ± 2.3

0.12

12.1 ± 2.5

11.8 ± 2.3

0.13

 ALT, U/L

595

37 [23, 85]

25 [17, 50]

NA

35 [21, 96]

26 [18, 56]

NA

 BNP, pg/mL

401

1451

[840, 3789]

1494

[772, 2560]

NA

1435

[840, 3810]

1751

[957, 2821]

NA

 HCO3, mmol/L

289

23.6 ± 5.8

25.9 ± 5.7

− 0.40

23.9 ± 6.4

25.2 ± 5.1

− 0.22

 Total bilirubin, mg/dL

413

1.7 ± 2.0

1.7 ± 2.1

0.01

1.7 ± 2.2

1.7 ± 2.7

0.00

 BUN, mg/dL

647

30.3 ± 15.8

29.8 ± 16.6

0.03

30.0 ± 16.1

31.2 ± 19.9

− 0.07

 Sodium, mg/dL

668

138.4 ± 5.3

139.6 ± 5.7

− 0.23

138.2 ± 5.1

139.4 ± 6.1

− 0.21

 Potassium, mg/dL

668

4.0 ± 0.6

3.9 ± 0.6

0.10

3.9 ± 0.6

4.0 ± 0.6

− 0.08

 Platelet, 1000/μL

662

182.9 ± 76.3

182.5 ± 81.0

0.01

179.9 ± 75.3

195.5 ± 87.0

− 0.19

 Hematocrit, %

664

36.4 ± 7.3

35.9 ± 6.7

0.07

36.5 ± 7.4

35.9 ± 6.6

0.08

 WBC, 1000/μL

663

10.2 ± 5.3

10.6 ± 5.1

− 0.07

9.7 ± 5.0

10.9 ± 4.8

− 0.25

 Albumin, mg/dL

456

3.4 ± 0.5

3.3 ± 0.5

0.07

3.4 ± 0.5

3.2 ± 0.5

0.33

 Lactate, mg/dL

263

28.6 ± 35.4

26.8 ± 20.5

0.07

27.7 ± 38.2

25.7 ± 20.5

0.07

 INR

506

1.3 ± 0.4

1.4 ± 0.4

− 0.22

1.3 ± 0.4

1.3 ± 0.4

− 0.07

  1. PSM propensity score matching, STD standard difference, LVEF left ventricular ejection fraction, eGFR estimated glomerular filtration rate, AMI acute myocardial infarction, PCI percutaneous coronary intervention, IABP intra-aortic balloon pumping, ICU intensive care unit, SOFA Sequential Organ Failure Assessment, APACHE Acute Physiology and Chronic Health Evaluation, ACEi angiotensin- converting enzyme inhibitor, ARBs angiotensin II receptor blockers, MRA mineralocorticoid receptor antagonist, ALT alanine aminotransferase, BNP B-type natriuretic peptide, BUN blood urea nitrogen, NA not available, WBC white blood count, INR international normalized ratio
  2. Data were presented as number (%), mean ± standard deviation or median [25th, 75th percentile];
  3. *Included in the calculation of propensity score